SEC Form 4 · accession 0001185185-18-000642
Genprex, Inc. · GNPX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
John Rodney Varner
Officer — Chief Executive Officer · Director · 10% Owner
Period of report
Mar 29, 2018
Accepted (ET)
Apr 5, 2018 · 4:57 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001595248
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Mar 29, 2018 | P | 10,000 | $5.00 | A | 544,735 | D | |
| Common Stock | holding | — | — | — | 1,614,152 | I | by Laura Lane Biosciences, LLC |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock option (right to buy)F1 | $0.96 | holding | — | — | — | — | Apr 11, 2026 | Common Stock | 645,572 | 645,572 | D |
Explanation of responses
- F1Fully vested.